The Inflammatory Marker suPAR After Cardiac Arrest
Soluble urokinase plasminogen activator receptor (suPAR) is released in response to inflammatory stimuli, and plasma levels are associated with long-term outcomes. The ischemia/reperfusion injury caused by cardiac arrest (CA) and resuscitation triggers an inflammatory response. This pilot study aimed at investigating suPAR levels in relation to outcome
Malin, Rundgren +3 more
openaire +3 more sources
The ELAVL1-PLAUR-suPAR Axis Exacerbates Diabetic Nephropathy by Promoting Podocyte Injury and Inflammation. [PDF]
This study identifies a novel pathogenic pathway in DN wherein hyperglycemia‐induced ELAVL1 upregulates PLAUR expression and promotes suPAR release from podocytes, leading to renal inflammation and injury. ABSTRACT Background Diabetic nephropathy (DN) is a leading cause of end‐stage renal disease.
Xu D, Xu L, Li L.
europepmc +2 more sources
suPAR, a Circulating Kidney Disease Factor [PDF]
Urokinase plasminogen activator receptor (uPAR) is a multifaceted, GPI-anchored three-domain protein. Release of the receptor results in variable levels of soluble uPAR (suPAR) in the blood circulation. suPAR levels have been linked to many disease states. In this mini-review, we discuss suPAR as a key circulating molecule mediating kidney disease with
Changli Wei +3 more
openaire +3 more sources
Low-Dose Fisetin Supplementation and Its Association With Chronic Inflammation in Middle-Aged and Older Adults: Study Protocol for a Triple-Blind, Randomised, Placebo-Controlled Trial. [PDF]
ABSTRACT Systemic chronic inflammation contributes to the development of many age‐related chronic diseases and represents a promising target for interventions aiming at promoting healthy aging. Fisetin is a naturally occurring flavonoid with anti‐inflammatory, antioxidant and senolytic effects in vitro and in animal models, but evidence from randomised
Tavenier J +15 more
europepmc +2 more sources
Exploring the Relationship Between Inflammatory Biomarkers and Negative Symptoms Subtypes in Individuals at Ultra-High Risk for Psychosis. [PDF]
ABSTRACT Aims Negative symptoms are a core component of schizophrenia, affecting up to 60% of individuals with the disorder. They are categorised into primary negative symptoms (PNS), which are intrinsic to the illness, and secondary negative symptoms, which arise from external factors such as depression or medication side effects.
Hakamuwa Lekamlage D +31 more
europepmc +2 more sources
Reassessing the Reassessment of suPAR in Glomerular Disease [PDF]
Soluble urokinase receptor (suPAR) is proposed as circulating factor in focal and segmental glomerulosclerosis (FSGS) (1). Spinale et al. attempt to validate the role of suPAR in glomerular disease (2). Their mouse overexpression experiments of physiological suPAR forms are distinct from the studies by Wei et al.
Björn eMeijers +2 more
openaire +3 more sources
Soluble urokinase plasminogen activator receptor (suPAR) results for determination of reference ...
Bruun, S (via Mendeley Data) +1 more
core +2 more sources
Soluble urokinase receptor (SuPAR) in COVID-19-Related AKI
Background AKI commonly occurs in patients with coronavirus disease 2019 (COVID-19). Its pathogenesis is poorly understood. The urokinase receptor system is a key regulator of the intersection between inflammation, immunity, and coagulation, and soluble ...
Solomonidi, N. +56 more
core +4 more sources
suPAR to Risk-Stratify Patients With Malaria
Severe malaria (SM) is a leading cause of global morbidity and mortality, particularly in children in sub-Saharan Africa. However, existing malaria diagnostic tests do not reliably identify children at risk of severe and fatal outcomes. Dysregulated host immune and endothelial activation contributes to the pathogenesis of SM.
Veselina Stefanova +10 more
openaire +3 more sources
suPAR and Team Nephrology [PDF]
Primary focal segmental glomerulosclerosis (FSGS) accounts for nearly 10 % of patients who require renal replacement therapy. Elevated circulating levels of soluble urokinase receptor (suPAR) have been identified as a biomarker to discriminate primary FSGS from other glomerulopathies.
openaire +2 more sources

